Project Grant R43HL176310
Award Date
9/17/24
Completion Date
8/31/25
Dollars Obligated
$304K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Endomimetics LLC (Q1CBADXNJSL5)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35242, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded Arizona State University a $407,975 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a lesion-targeted nanotherapeutic for treating vascular smooth muscle cell (VSMC) dysfunction and neointimal hyperplasia (NIH). The research project aims to integrate in vitro transcribed CARMN RNA, a long non-coding RNA critical for VSMC differentiation, into...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $700,398 to conduct research on identifying new molecular and cell-specific mechanisms of atherosclerotic cardiovascular disease (CVD) plaque vulnerability. The research aims to integrate spatial transcriptomics, genetics, and histomorphology using human and mouse atherosclerotic lesion samples...
The National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research Program (CFDA 93.837), awarded a $400,000 Project Grant to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The grant supports the development of an advanced analytical testing device to quantitatively characterize lipoprotein particles in blood. Lipoproteins are key indicators of cardiovascular disease risk, as certain classes can contribute to the buildup...
The federal Project Grant award R01HL177553 for $787,267, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to determine whether genetic deletion or pharmacological inhibition of the DHCR24 enzyme in macrophages and hepatocytes can increase desmosterol levels and reduce vascular inflammation, thereby attenuating the progression of atherosclerosis. The research will leverage novel animal models and...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to characterize the role of adventitial fibroblasts in atherosclerosis development and progression. The $705,405 award to The Leland Stanford Junior University will fund a 5-year project to identify novel mechanisms by which adventitial fibroblasts influence atherosclerotic plaque formation and calcification. The...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support a research initiative led by Yale University to develop a predictive computational model of vascular remodeling. The $686,458 award, effective July 10, 2024 through May 31, 2028, will fund a collaborative research effort across three labs to acquire quantitative data on regulatory networks governing vascular remodeling...
This $3,685,958 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), supports research to develop a novel orally bioavailable drug for lowering cholesterol levels. The grant aims to complete key IND-enabling studies, including toxicology testing in dogs, safety pharmacology, and FDA regulatory support, to enable initiation of a Phase I clinical trial for the candidate PCSK9/LDLR antagonist compound "P-21"....
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research program (CFDA 93.837), aims to determine whether inducing the protein RECK can serve as a novel therapeutic approach to prevent the development and progression of atherosclerosis. The $646,106 award will fund research at Tulane University to investigate how RECK overexpression in vascular smooth muscle cells and macrophages can inhibit inflammation, promote...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to define cellular pathways that regulate lipid flux and elucidate their impact on cardiovascular disease. The $773,259 award to the University of California, Los Angeles (UCLA) aims to: 1) identify novel cholesterol-responsive proteins in the vasculature, 2) define molecular mechanisms whereby membrane cholesterol...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, with a period of performance from January 2, 2025 to December 31, 2027, will support research to develop microphysiological systems that can precisely control oxygen levels to investigate the molecular pathways and functional effects of hypoxic injury on cardiomyocytes. The research aims to obtain a...